Back to top
more

ShockWave Medical (SWAV)

(Delayed Data from NSDQ)

$330.55 USD

330.55
429,386

+0.01 (0.00%)

Updated May 10, 2024 04:00 PM ET

After-Market: $330.53 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy as Inflation Clouds Prospects

The Zacks Medical - Instruments industry is growing on rising demand for digital health. SWAV, MLAB and DYNT are set to gain the most. Yet, the ongoing inflation in the form of rising freight, raw material and labor costs is an overhang.

3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio

Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.

Alcon (ALC) Q3 Earnings Surpass Estimates, Sales Guidance Cut

Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the strength in its comprehensive portfolio of PCIOLs, including PanOptix and Vivity.

PerkinElmer's (PKI) New Viral Vector Assays to Boost Workflows

PerkinElmer's (PKI) latest launch is expected to help researchers expand options to measure viral titers, unlike ELISA and other wash-based systems.

Encompass Health (EHC) Proposes 50-Bed Hospital in Florida

Encompass Health (EHC) intends to build a 50-bed inpatient rehabilitation hospital in the Daytona Beach area to further amplify its presence in Florida.

Here's Why You Should Bet on ShockWave Medical (SWAV) Stock

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Medtronic (MDT) Q2 Earnings Beat Estimates, Margins Down

Medtronic's (MDT) Q2 organic revenues reflect slower supply recovery and lower-than-anticipated underlying market procedure volumes in certain businesses.

Here's Why You Should Hold on to Abiomed (ABMD) Stock Now

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Merit Medical's (MMSI) New Launch to Boost Patient Outcome

Merit Medical's (MMSI) latest addition to its radial portfolio is expected to significantly optimize hemostasis for radial artery procedures.

SmileDirectClub (SDC) Q3 Earnings Beat, Gross Margin Dips

Challenges to consumer spending and sustained high inflation continue to impact SmileDirectClub's (SDC) overall expected demand for 2022.

Henry Schein's (HSIC) New Deal to Improve Patient Outcome

Henry Schein's (HSIC) recent deal with Rimidi is expected to aid healthcare professionals in enhancing chronic disease management.

What's in the Cards for Medtronic (MDT) in Q2 Earnings?

Medtronic's (MDT) Evolut PRO+ launch in Europe and Evolut PRO launch in China are expected to have contributed to the company's fiscal Q3 top line.

Neogen's (NEOG) Synergize Disinfectant Now Widely Available

Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

Sector ETF report for XHE

NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut

The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.

Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Cardinal Health's (CAH) Velocare to Enhance at-Home Care

Cardinal Health's (CAH) latest launch is expected to significantly expand its at-Home Solutions supply chain and logistics services, thereby improving patient care.

3 Reasons to Retain Abbott (ABT) Stock in Your Portfolio

Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business.

PerkinElmer's (PKI) New Marketing Approval to Aid Infant Health

PerkinElmer's (PKI) EONIS SCID-SMA assay kit is expected to enable early SMA and SCID screening in newborns following the FDA's approval.

Phibro (PAHC) Q1 Earnings Miss Estimates, Sales Surpass

Phibro's (PAHC) growing uptake of MFAs, dairy products and vaccines buoys optimism.

Here's Why You Should Retain Cooper Companies (COO) Stock Now

Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.

Patterson Companies' (PDCO) New Buyout to Expand Product Suite

Patterson Companies' (PDCO) latest buyout is expected to significantly expand its Animal Health's product offerings.

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates

Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) third-quarter results benefit from the Technologies & Equipment business.

Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment

Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.